Weekly FDA Roundup: US-EU Pharma Deal Revoked, Blood Glucose Device Death, and 8 Class I Recalls — Week of Feb 14–21, 2026
FDA revokes the US-EU pharmaceutical GMP mutual recognition agreement effective March 23, while a blood glucose correction links 114 injuries and one death to an error-code flaw, and five simultaneous Class I recalls sweep a hummus brand.
FDA enforcement took a sharp geopolitical turn this week: a final rule published February 19 tears up the longstanding mutual recognition agreement (MRA) with the European Community for pharmaceutical GMP inspections and medical device audit reports—effective March 23. Combined with 28 recalls including a hummus brand's five-product Class I sweep, a fatal blood glucose device correction, and a major animal health company's warning letter for misleading antibiotic marketing, the week of February 14–21, 2026 delivered regulatory whiplash across multiple sectors.
By the Numbers
- 59 total items published Feb 14–21, 2026
- 28 recalls (8 Class I, 19 Class II, 1 Class III)
- 4 warning letters (3 CGMP/misbranding, 1 import)
- 2 final rules (including the MRA revocation)
- 1 safety alert (medical device, 1 death reported)
- 24 notices (traceability guidance, ANDA withdrawals, debarments)
- Key deadline: MRA revocation takes effect March 23, 2026
Lead Story: FDA Tears Up the US-EU Pharmaceutical GMP Deal
On February 19, FDA published a final rule revoking 21 CFR Part 26, which has governed the mutual recognition of pharmaceutical good manufacturing practice (GMP) reports and medical device quality system audit reports between the United States and the European Community since the late 1990s.
Effective March 23, 2026, the rule is gone.
What this means in practice: under the MRA, FDA and European Medicines Agency (EMA) inspection bodies had agreed to recognize each other's GMP audits for pharmaceutical manufacturers. A U.S. drug company manufacturing in Ireland or Germany could rely on an EMA inspection rather than waiting for an FDA inspector to fly over. That mutual trust is now formally revoked.
The revocation fits a broader pattern visible in the agency's regulatory agenda under the current administration: rolling back international harmonization frameworks established in prior decades. The same February 19 Federal Register edition included a separate final rule revoking 21 CFR Part 2's "Methods of Analysis" regulation—another deregulatory cleanup, though far less consequential.
The revocation also arrives as a context signal: FDA's appetite for international regulatory equivalence deals appears to be contracting, not expanding. Watch for downstream effects on other bilateral frameworks, particularly with Japan (ICH) and Canada.
Key Developments
Trividia Health Blood Glucose Correction: 114 Injuries, 1 Death
On February 17, FDA issued an Early Alert for an urgent correction to Trividia Health's TRUE METRIX, TRUE METRIX AIR, TRUE METRIX GO, and TRUE METRIX PRO blood glucose monitoring systems.
The issue: the original instructions for the E-5 error code—which signals either a very high blood glucose result or a test strip error—failed to instruct users to seek immediate medical attention if they were experiencing symptoms of high glucose. Patients who misread the error as a strip malfunction and waited could face dehydration, altered mental status, or death. As of January 16, 2026, 114 serious injuries and one death have been associated with this failure mode.
The correction updates the E-5 guidance to explicitly direct users to seek immediate medical care when the error appears alongside high-glucose symptoms. This is a label and instructions correction, not a device replacement.
Who should care: Diabetes device manufacturers and distributors; any company with self-monitoring blood glucose systems that display error codes without unambiguous clinical guidance. The FDA's post-market surveillance system captured 114 adverse events before this correction was issued—companies should audit their own error-code language proactively.
Elanco Animal Health: Pradalex Antibiotic Marketing Called Out
Elanco Animal Health USA received a warning letter for its marketing of Pradalex (pradofloxacin injection), a fluoroquinolone antibiotic for bovine and swine respiratory disease.
FDA's Center for Veterinary Medicine found that Elanco's promotional materials described Pradalex as a "first-pull treatment" effective against "all relevant" pathogens—claims the agency determined were unsubstantiated and directly contradicted the approved label. The label restricts pradofloxacin's use due to fluoroquinolone antimicrobial resistance concerns; the marketing materials effectively undermined those restrictions.
Additional comparative claims about the drug's speed and "power" relative to competitors were also flagged as misleading under 21 U.S.C. 352(a) and 352(n), constituting misbranding under the FD&C Act.
Who should care: Veterinary pharmaceutical companies, especially those marketing antibiotics with restricted-use labels. This is the kind of case that signals CVM is actively reviewing promotional materials for consistency with label restrictions—not just efficacy claims, but antimicrobial stewardship language.
Carrot Top Kitchens: Five Class I Hummus Recalls in One Day
On February 18, Carrot Top Kitchens LLC triggered five simultaneous Class I recalls covering its entire hummus line: Sundried Tomato and Caper, Lime Ginger, Lemon & Garlic, White Truffle, and Cherry Pepper varieties.
Class I is FDA's most serious recall classification, reserved for products with a reasonable probability of causing serious adverse health consequences or death. The scope—five SKUs recalled on the same date from a single manufacturer—suggests a production or labeling failure affecting the full product line rather than a single batch. The likely culprit: undeclared allergens, given the prevalence of tahini (sesame) across hummus products and the trajectory of sesame as a top-10 allergen in FDA's current enforcement data.
Kirkland Signature Costco Mini Beignets (Costco Wholesale Corporation) also received a Class I recall on February 18.
Who should care: Food manufacturers and co-packers with allergen control programs; retailers carrying Carrot Top Kitchens products. Five simultaneous Class I recalls from a single brand is a red flag for allergen cross-contact or labeling batch errors affecting all production runs.
11 Generic Drug Approvals Pulled: Masuu Global Solutions / Extrovis AG
A notice published February 20 announced FDA's withdrawal of approval of 11 Abbreviated New Drug Applications held by Masuu Global Solutions LLC, U.S. agent for Extrovis AG. This effectively removes 11 generic drug products from the U.S. market.
Mass ANDA withdrawals of this nature typically follow inability to meet FDA post-approval requirements, failure to launch marketed products within a defined window, or the agency's own dossier reviews. Eleven ANDAs at once is notable—this is a clean sweep, not a routine administrative update.
FSMA Traceability Updates: Cottage Cheese Gets a Pass, Guidance Opens for Comment
Two February 20 notices moved the FSMA Food Traceability Rule implementation forward:
-
Cottage cheese exemption: FDA published a notification of exemption for cottage cheese regulated under the National Conference on Interstate Milk Shipments (NCIMS) Grade "A" Pasteurized Milk Ordinance from the Food Traceability Rule's additional record-keeping requirements.
-
Draft Q&A guidance: FDA released a draft guidance document answering questions about the traceability records requirements for covered foods. Comment deadline: May 21, 2026.
Who should care: Food manufacturers across the supply chain covered by the Traceability Rule. The Q&A guidance is an important implementation document—comment if your operations have edge cases or ambiguities the current rule text doesn't resolve.
The Bigger Picture
Zoom out to the 28-day window and the dominant story is still the compounding crackdown: semaglutide (29 items) and tirzepatide (27 items) are the top two substances in FDA's enforcement data, with compounded drugs representing 36 of 249 total items. Warning letters to telehealth companies marketing compounded GLP-1s—which hit in volume the following week—were visibly building in the pipeline.
The US-EU MRA revocation fits a theme of active deregulation combined with selective re-enforcement: FDA is stripping away international cooperation frameworks it sees as redundant or politically inconvenient while simultaneously intensifying domestic enforcement on specific categories (GLP-1 compounding, drug advertising, allergen labeling).
For medical device makers, the Trividia correction is a reminder that the post-market surveillance system is generating actionable signals even as the FDA's device regulatory posture continues to evolve. 114 adverse events in the MAUDE database before a correction was issued is a data pattern companies should benchmark against their own vigilance programs.
Recall classification breakdown for the broader period: Class II dominates at 545 total vs. 399 Class I across the full dataset—but the week of Feb 18 bucked that trend, with 8 of 28 recalls earning Class I status.
What to Watch
- March 23, 2026: MRA revocation effective. Pharma and device companies with EU manufacturing need clarity on FDA inspection expectations before this date.
- April 21, 2026: Comment deadline on multiple FDA information collection proposals (CGMP drugs, fish/fishery HACCP, animal drug adverse events).
- May 21, 2026: Comment deadline on FSMA Food Traceability Rule Q&A draft guidance.
- Compounded GLP-1 enforcement: The pipeline of warning letters to telehealth companies was about to open wide—30 letters dropped the following week. If you operate in the GLP-1 space, audit your marketing claims now.
Policy Canary monitors FDA changes for your specific products—by name, by ingredient, by category. No more scanning the Federal Register yourself. Join the pilot program.
Get this in your inbox every Friday.
Free FDA intelligence digest. No account required.
